19 / 34
Page 56
Journal of Clinical Immunology and Allergy
ISSN: 2471-304X
16
th
EuroSciCon Conference on
Immunology
M a r c h 1 1 - 1 2 , 2 0 1 9
Am s t e r d a m , N e t h e r l a n d s
Immunology 2019
A
driblastin-Bleomycin-Vincristin (ABV) chemotherapy has improved the survival of Kaposi Sarcoma (KS) infected people.
In human herpes virus-8 (HHV-8, the causative agent of KS) endemic areas, the immune system is in the constant rate of
activation, leading to a chronic immune activation against the virus. This chronic activation can leads to immune cells progressive
depletion as T-lymphocytes and/or to inflammatory reaction and represent a major concern in patient care. However, many
markers can measure those dysfunctions and they are often used without accounting for their possible interdependency. In the
order to better understand the impact of this chemotherapy on the dynamics of immune activation and associated inflammation
markers in Kaposi Sarcoma patients, the use of PCA for such task could be beneficial. In this view, four markers such as CD4
T-lymphocytes, IgG, Il-6 and Il-10 from the analysis of blood samples, collected between 1
st
Jul’ 2014 and 31
st
Dec’ 2015, on a
total of 52 SK patients at the Yaoundé General Hospital, were analyzed. KS advanced stages and progressive response variables
were associated to abnormal biomarkers levels post ABV therapy. At the end of this work, the ABV chemotherapy impacts on
CD4 evolution and the persistence of biomarkers abnormal levels post treatment were observed. These results suggested that
chemotherapy was not efficient to rise up immune activation and inflammation biomarkers to normal level.
j.njikibikoi@yahoo.frApplication of the principal components analysis
for the assessment of the relief rate after the
initiation of chemotherapy in Cameroonian Kaposi
Sarcoma’s patients
Jacky Njiki Bikoi
1
, P Ndom
2
, D S Mbaga
3
, S H Riwom
4
and
F X Etoa
5
University of Yaoundé 1, Cameroon
J Clin Immunol Allergy 2019, Volume:5
DOI: 10.21767/2471-304X-C1-009